# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Anupam Rama upgrades Replimune Group (NASDAQ:REPL) from Underweight to Neutral and announces $11 price tar...
Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory update.
Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perform to Outperform and raises ...
Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform and raises the price targe...
REPL: 81% | The FDA Accepts Replimune's Resubmission Of The Biologics License Application For RP1 In Combination With Nivol...